- Company’s IP portfolio, including proprietary technology and biosynthetic methods, features seven U.S. patents and patent filings in numerous other key countries around the world
- Eliminating the high costs of cultivating plants, Teewinot Life Sciences Corporation delivers pure, consistent pharmaceutical-grade cannabinoids
- Company’s goal is to cut costs and approach cannabinoid production like a pharmaceutical company, not as a cannabis firm
Teewinot Life Sciences Corporation has an advantage in consistently producing pure, clinical-grade cannabinoids with its patented biosynthetic technology. The results eliminate the watering and electrical costs of traditional plant cultivation, as well as the variances in quality. Instead, its method offers low-cost cannabinoids in a pure, consistent clinical grade.
Teewinot Life Sciences is a Tampa, Florida-based global biopharmaceutical company focused on cannabinoid clinical development utilizing patented and proprietary synthetic biology and biocatalysis technology. Its strategy involves the production and use of cannabinoid molecules. The goal of the company is to produce, at lower cost, consistent and pure cannabinoids that it believes can be used to develop superior human therapies.
The company and its wholly-owned subsidiaries have patented technologies that produce individual cannabinoids at commercial scale for a wide variety of markets. It approaches the process as a straight medical company, not as a marijuana firm. Its process involves the pharmaceutical manufacture of cannabinoids through biocatalysis and synthetic biology.
Cannabinoid biosynthetic enzymes are produced in microorganisms transformed with cannabinoid biosynthetic genes. Those enzymes are then used to manufacture pharmaceutically-pure cannabinoids.
The goal is to improve human therapies. The company has now secured seven U.S. patents and has a portfolio of patent applications in a number of countries. Teewinot Life Sciences has subsidiaries in Ireland and Canada.
For more information, visit the company’s website at www.TLSCorp.com
More from CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com